Cerebral metabolic abnormalities in A3243G mitochondrial DNA mutation carriers

Neurology

Volumn 82, Issue 9, 2014, Pages 798-805

  Weiduschat, Nora ^a   Kaufmann, Petra ^b   Mao, Xiangling ^a   Engelstad, Kristin Marie ^b   Hinton, Veronica ^b   DiMauro, Salvatore ^a   De Vivo, Darryl ^b   Shungu, Dikoma ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHOLINE; CREATINE; LACTIC ACID; MITOCHONDRIAL DNA; N ACETYLASPARTIC ACID;

ARTICLE; BIOSYNTHESIS; BRAIN METABOLISM; CELL ENERGY; COHORT ANALYSIS; ENERGY METABOLISM; FOLLOW UP; GENE MUTATION; HETEROZYGOTE; MELAS SYNDROME; METABOLIC DISORDER; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTON NUCLEAR MAGNETIC RESONANCE;

ACIDOSIS, LACTIC; ADULT; AGED; ASPARTIC ACID; CEREBRAL CORTEX; CHOLINE; CREATINE; DNA, MITOCHONDRIAL; FEMALE; HUMANS; LACTIC ACID; LONGITUDINAL STUDIES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MELAS SYNDROME; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES;

EID: 84895760422     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000169     Document Type: Article

References (40)

1. Hirano M, Pavlakis SG. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): Current concepts. J Child Neurol 1994;9:4-13.
2. Goto Y, Nonaka I, Horai S. A mutation in the tRNA(Leu) (UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990;348:651-653.
3. Graham BH. Diagnostic challenges of mitochondrial disorders: Complexities of two genomes. Methods Mol Biol 2012;837:35-46.
4. Kaufmann P, Engelstad K,Wei Y, et al. Protean phenotypic features of the A3243G mitochondrial DNA mutation. Arch Neurol 2009;66:85-91.
5. Kaufmann P, Shungu DC, Sano MC, et al. Cerebral lactic acidosis correlates with neurological impairment in MELAS. Neurology 2004;62:1297-1302.
6. Dubeau F, De Stefano N, Zifkin BG, et al. Oxidative phosphorylation defects in the brains of carriers of the tRNAleu(UUR) A3243G mutation in a MELAS pedigree. Ann Neurol 2000;47:179-185.
7. Ito H, Mori K, Harada M, et al. Serial brain imaging analysis of stroke-like episodes in MELAS. Brain Dev 2008;30: 483-488.
8. Feng F, You H, Gao J, et al. Evaluation of mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes with magnetic resonance imaging and proton magnetic resonance spectroscopy. Chin Med Sci J 2006; 21:234-238.
9. Chen C, Xiong N, Wang Y, et al. A study of familial MELAS: Evaluation of A3243G mutation, clinical phenotype, and magnetic resonance spectroscopy- monitored progression. Neurol India 2012;60:86-89.
10. Lin DD, Crawford TO, Barker PB. Proton MR spectroscopy in the diagnostic evaluation of suspected mitochondrial disease. AJNR Am J Neuroradiol 2003;24:33-41.
11. Duyn JH, Gillen J, Sobering G, van Zijl PC, Moonen CT. Multisection proton MR spectroscopic imaging of the brain. Radiology 1993;188:277-282.
12. Kaufmann P, Engelstad K, Wei Y, et al. Natural history of MELAS associated with mitochondrial DNA m. 3243A.G genotype. Neurology 2011;77:1965-1971.
13. Pearson TS, Akman C, Hinton VJ, Engelstad K, De Vivo DC. Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS). Curr Neurol Neurosci Rep 2013;13:342.
14. Kaufmann P, Koga Y, Shanske S, et al. Mitochondrial DNA and RNA processing in MELAS. Ann Neurol 1996;40:172-180.
15. Buck LT, Pamenter ME. Adaptive responses of vertebrate neurons to anoxia: Matching supply to demand. Respir Physiol Neurobiol 2006;154:226-240.
16. Möller HE, Kurlemann G, Pützler M, Wiedermann D, Hilbich T, Fiedler B. Magnetic resonance spectroscopy in patients with MELAS. J Neurol Sci 2005;229-230:131-139.
17. Wilichowski E, Pouwels PJ, Frahm J, Hanefeld F. Quantitative proton magnetic resonance spectroscopy of cerebral metabolic disturbances in patients with MELAS. Neuropediatrics 1999;30:256-263.
18. Mathews PM, Andermann F, Silver K, Karpati G, Arnold DL. Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. Neurology 1993; 43:2484-2490.
19. Tsujikawa T, Yoneda M, Shimizu Y, et al. Pathophysiologic evaluation of MELAS strokes by serially quantified MRS and CASL perfusion images. Brain Dev 2010;32: 143-149.
20. Birken DL, Oldendorf WH. N-acetyl-L-aspartic acid: A literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev 1989;13:23-31.
21. Saneto RP, Friedman SD, Shaw DW. Neuroimaging of mitochondrial disease. Mitochondrion 2008;8:396-413.
22. Wiesner RJ. Adaptation of mitochondrial gene expression to changing cellular energy demands. News Physiol Sci 1997;12:178-184.
23. Wredenberg A, Wibom R, Wilhelmsson H, et al. Increased mitochondrial mass in mitochondrial myopathy mice. Proc Natl Acad Sci USA 2002;99:15066-15071.
24. Wiesner RJ, Hornung TV, Garman JD, Clayton DA, O'Gorman E, Wallimann T. Stimulation of mitochondrial gene expression and proliferation of mitochondria following impairment of cellular energy transfer by inhibition of the phosphocreatine circuit in rat hearts. J Bioenerg Biomembr 1999;31:559-567.
25. Rollins S, Prayson RA, McMahon JT, Cohen BH. Diagnostic yield of muscle biopsy in patients with clinical evidence of mitochondrial cytopathy. Am J Clin Pathol 2001; 116:326-330.
26. DiMauro S, Bonilla E, Zeviani M, et al. Mitochondrial myopathies. Ann Neurol 1985;17:521-538.
27. De Vivo DC, DiMauro S. Mitochondrial defects in brain and muscle. Biol Neonate 1990;58(suppl 1):54-69.
28. Johnson HA, Amendola F. Mitochondrial proliferation in compensatory growth of the kidney. Am J Pathol 1969;54: 35-45.
29. Goffart S, von Kleist-Retzow JC, Wiesner RJ. Regulation of mitochondrial proliferation in the heart: Power-plant failure contributes to cardiac failure in hypertrophy. Cardiovasc Res 2004;64:198-207.
30. Sebastiani M, Giordano C, Nediani C, et al. Induction of mitochondrial biogenesis is a maladaptive mechanism in mitochondrial cardiomyopathies. J Am Coll Cardiol 2007; 50:1362-1369.
31. Irrcher I, Adhihetty PJ, Joseph AM, Ljubicic V, Hood DA. Regulation of mitochondrial biogenesis in muscle by endurance exercise. Sports Med 2003;33:783-793.
32. Zong H, Ren JM, Young LH, et al. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci USA 2002;99:15983-15987.
33. Tokunaga M, Mita S, Sakuta R, Nonaka I, Araki S. Increased mitochondrial DNA in blood vessels and ragged-red fibers in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). Ann Neurol 1993;33:275-280.
34. Heddi A, Stepien G, Benke PJ, Wallace DC. Coordinate induction of energy gene expression in tissues of mitochondrial disease patients. J Biol Chem 1999;274:22968-22976.
35. Shungu DC, Mao X, Johnson CE, et al. 1H MRSI detection of elevated total creatine in brain cancer: A cautionary tale. Proc Soc Magn Reson Med 2009;17:1008.
36. Toback FG, Smith PD, Lowenstein LM. Phospholipid metabolism in the initiation of renal compensatory growth after acute reduction of renal mass. J Clin Invest 1974;54: 91-97.
37. Herminghaus S, Pilatus U, Möller-Hartmann W, et al. Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed 2002;15:385-392.
38. Bianchi MC, Tosetti M, Battini R, et al. Proton MR spectroscopy of mitochondrial diseases: Analysis of brain metabolic abnormalities and their possible diagnostic relevance. AJNR Am J Neuroradiol 2003;24:1958-1966.
39. Takahashi S, Oki J, Miyamoto A, Okuno A. Proton magnetic resonance spectroscopy to study the metabolic changes in the brain of a patient with Leigh syndrome. Brain Dev 1999;21:200-204.
40. Friedman SD, Shaw DW, Ishak G, Gropman AL, Saneto RP. The use of neuroimaging in the diagnosis of mitochondrial disease. Dev Disabil Res Rev 2010; 16:129-135.